Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Gilead

    - PMLiVE

    Roche’s Columvi improves survival in large B-cell lymphoma

    Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

    The recommendation for the subcutaneous formulation follows encouraging trial data

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis

    The company gained access to the drug through its $4.3bn acquisition of CymaBay in March

    - PMLiVE

    Kite and Arcellx expand cell therapy partnership in deal worth over $285m

    The companies' existing CART-ddBCMA collaboration now covers lymphomas

    - PMLiVE

    Roche’s fixed-duration lymphoma treatment approved by European Commission

    Approximately 36,000 people are diagnosed with DLBCL each year in Europe

    - PMLiVE

    ADC Therapeutics pauses enrolment in phase 2 lymphoma study following patient deaths

    Zynlonta was being evaluated along with rituximab in unfit or frail patients with DLBCL

    - PMLiVE

    Kite’s CAR-T therapies recommended by NICE for certain blood cancers

    The two treatments could benefit up to 600 patients each year in England

    - PMLiVE

    Gilead’s Trodelvy shows promise in phase 2 bladder cancer study

    An estimated 83,000 Americans will be diagnosed with bladder cancer in 2023

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links